Srikumar Sahasranaman

Author

University of Florida ORCID

Also Known As

S Sahasranaman, S. Sahasranaman, Sahasranaman Srikumar, Srikumar Sahasranaman

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

University of Florida Shanghai Huayi Group (China)BeiGene (China)Sunesis (United States)Frankston Hospital

About

Srikumar Sahasranaman is an author at University of Florida specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	365
2	Allergy	2	2	22
3	Health Sciences	1	1	13
4	Natural Sciences	1	1	11
5	Social Sciences	1	1	107

Srikumar Sahasranaman

Publications

881

Citations

H-Index

Page 1

	Year	Citations
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia Thomas J. Kipps, Herbert Eradat, Sebastian Grosicki, Leukemia & lymphoma/Leukemia and lymphoma Arm BTumor BiologyBiologic ActivityLymphoid NeoplasiaHematological Malignancy	2015	186
The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys Laurent Grégoire, Nicolas Morin, Bazoumana Ouattara, Parkinsonism & Related Disorders NeurophysiologyMedicineNeurotransmitterNeuropharmacologyNeuroprotection	2011	107
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors Jeffrey R. Infante, Antoine Hollebecque, Sophie Postel‐Vinay, Clinical Cancer Research	2016	70
Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma Kevin Mortimer, Tim Harrison, Yufei Tang, British Journal of Clinical Pharmacology	2006	51
Model-Based Covariate Pharmacokinetic Analysis and Lack of Cortisol Suppression by the New Inhaled Corticosteroid Ciclesonide Using a Novel Cortisol Release Model Shashank Rohatagi, Sriram Krishnaswami, Marc Pfister, American Journal of Therapeutics	2005	45
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects Song Mu, Zhiyu Tang, William Novotny, Cancer Chemotherapy and Pharmacology	2019	39
Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids Manish Issar, Srikumar Sahasranaman, Péter Buchwald, European Respiratory Journal	2006	38
GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study Kit Wun Kathy Cheung, Kenta Yoshida, Sravanthi Cheeti, Drug Metabolism and Disposition	2019	33
Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects Lichuan Liu, Sravanthi Cheeti, Kenta Yoshida, The Journal of Clinical Pharmacology	2018	32
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma Ying Ou, Zhiyu Tang, William Novotny, Leukemia & lymphoma/Leukemia and lymphoma	2021	31

Page 1